Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single daily pill slash heart disease risks?

NCT ID NCT06930885

Recruiting now Disease control Sponsor: Hospital do Coracao Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

The EPOCA trial is testing whether a daily 'polypill' (combining blood pressure, cholesterol, and blood-thinning medications) plus the anti-inflammatory drug colchicine can reduce major heart and limb events in people with established heart disease. Over 7,700 participants aged 45 and older with a history of heart attacks, strokes, or artery blockages will be followed for several years. The goal is to see if this simpler, combined approach lowers the risk of cardiovascular death, heart attack, stroke, urgent artery procedures, and leg amputations better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A combination pill containing valsartan (blood pressure drug), atorvastatin (cholesterol drug), and aspirin (blood thinner), plus the anti-inflammatory drug colchicine.
What this could lead to
If successful, this could provide a simple, once-daily pill regimen that significantly lowers the risk of heart attacks, strokes, and limb amputations in people with established heart disease.
What could go wrong
This is a large Phase 3 trial, but the polypill and colchicine are already approved drugs, so the main question is whether combining them works better than current standard care. Side effects like muscle pain, bleeding, or stomach issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) ATHEROTHROMBOTIC DISEASES

Contacts and locations

Locations

  • CIPES - Centro Internacional de Pesquisa Clínica

    RECRUITING

    São José dos Campos, São Paulo, Brazil

  • CMEP - Centro Multidisciplinar de Ensino especializado e Pesquisa

    RECRUITING

    Joinville, Santa Catarina, Brazil

  • Centro de Pesquisa Cardiolima

    RECRUITING

    Teresina, Piauí, Brazil

    Contact Email: •••••@•••••

  • Centro de Pesquisa Cetrus

    RECRUITING

    São Paulo, São Paulo, Brazil

  • Centro de Pesquisas Clínicas Dr. Marco Mota

    RECRUITING

    Maceió, Alabama, 57051160, Brazil

    Contact Email: •••••@•••••

  • Empresa Brasileira de Serviços Hospitalares - EBSERCH - Hospital de Ensino Dr. Washington Antônio de Barros- HU-UNIVASF

    RECRUITING

    Petrolina, Pernambuco, Brazil

  • Fundação Faculdade Regional de Medicina São José do Rio Preto

    RECRUITING

    São José do Rio Preto, São Paulo, 15.090-000, Brazil

  • Fundação Técnico Educacional Souza Marques

    RECRUITING

    Rio de Janeiro, Rio de Janeiro, 22.793-140, Brazil

  • Fundação Universitária de Cardiologia - ICFUC

    RECRUITING

    Porto Alegre, Rio Grande do Sul, Brazil

    Contact Email: •••••@•••••

  • Hcor

    RECRUITING

    São Paulo, São Paulo, 04004-030, Brazil

  • Hospital Universitário São Francisco na Providência de Deus

    RECRUITING

    Bragança Paulista, São Paulo, Brazil

  • Instituto de Pesquisa e Ensino em Saúde - IPES

    RECRUITING

    Porto Velho, Rondônia, Brazil

  • Secretária da Saúde do Estado do Ceará - Hospital de Messejana Dr. Carlos Alberto Studart Gomes

    RECRUITING

    Messejana, Ceará, Brazil

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.